文献速递胸部肿瘤

HER4与EGFR在NRG1融合驱动癌症中激活细胞信号传导:对HER2-HER3特异性靶向与泛HER靶向策略的启示

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
PubMed 文献 · J Thorac Oncol · 2023-09-09

本研究利用Ba/F3模型及体外体内模型,探讨HER4和EGFR-HER3信号在NRG1融合阳性癌症中的作用。发现NRG1融合可通过HER4独立驱动下游信号和肿瘤生长,EGFR-HER3信号亦被激活,联合抑制这些受体才能有效抑制肿瘤生长;西妥昔单抗联合曲妥珠单抗和帕妥珠单抗产生协同效应,泛HER酪氨酸激酶抑制剂比针对EGFR、EGFR-HER2或HER2-HER4的高选择性抑制剂更有效。结论提示,在NRG1融合阳性癌症中,包括HER4和EGFR阻断在内的泛HER抑制比选择性靶向HER3或HER2-HER3更有效。

要点

  • NRG1融合可通过HER4独立于其他HER家族成员刺激下游信号和肿瘤细胞生长。
  • EGFR-HER3信号在表达NRG1融合的细胞中也被激活,抑制这些受体对有效抑制肿瘤生长同样必要。
  • 泛HER酪氨酸激酶抑制剂比针对EGFR、EGFR-HER2或HER2-HER4的高选择性抑制剂更有效,但不同NRG1融合阳性癌症对EGFR或HER4信号的相对依赖程度存在差异。

核心结论

  • 研究结果表明,在NRG1融合阳性癌症中,包括HER4和EGFR阻断在内的泛HER抑制比选择性靶向HER3或HER2-HER3更有效。

研究设计与样本

  • 研究使用工程化表达多种HER家族成员联合NRG1融合的Ba/F3模型,以及NRG1融合阳性癌症的体外和体内模型,探讨HER4和EGFR-HER3信号的作用。

主要发现

  • NRG1融合可通过HER4独立于其他HER家族成员刺激下游信号和肿瘤细胞生长。
  • EGFR-HER3信号在表达NRG1融合的细胞中也被激活,抑制这些受体对有效抑制肿瘤细胞生长同样必要。
  • 抗EGFR抗体西妥昔单抗联合抗HER2抗体曲妥珠单抗和帕妥珠单抗产生协同效应。
  • 泛HER酪氨酸激酶抑制剂比针对EGFR、EGFR-HER2或HER2-HER4的高选择性酪氨酸激酶抑制剂更有效,但不同NRG1融合阳性癌症对EGFR或HER4信号的相对依赖程度存在差异。

临床怎么用

  • 作者结论认为,在NRG1融合阳性癌症中,包括HER4和EGFR阻断在内的泛HER抑制比选择性靶向HER3或HER2-HER3更有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: NRG1 gene fusions are clinically actionable alterations identified in NSCLC and other tumors. Previous studies have reported that NRG1 fusions signal through HER2 and HER3 but, thus far, strategies targeting HER3 specifically or HER2-HER3 signaling have exhibited modest activity in patients with NSCLC bearing NRG1 fusions. Although NRG1 fusion proteins can bind HER4 in addition to HER3, the contribution of HER4 and other HER family members in NRG1 fusion-positive cancers is not fully understood. METHODS: We investigated the role of HER4 and EGFR-HER3 signaling in NRG1 fusion-positive cancers using Ba/F3 models engineered to express various HER family members in combination with NRG1 fusions and in vitro and in vivo models of NRG1 fusion-positive cancer. RESULTS: We determined that NRG1 fusions can stimulate downstream signaling and tumor cell growth through HER4, independent of other HER family members. Moreover, EGFR-HER3 signaling is also activated in cells expressing NRG1 fusions, and inhibition of these receptors is also necessary to effectively inhibit tumor cell growth. We observed that cetuximab, an anti-EGFR antibody, in combination with anti-HER2 antibodies, trastuzumab and pertuzumab, yielded a synergistic effect. Furthermore, pan-HER tyrosine kinase inhibitors were more effective than tyrosine kinase inhibitors with greater specificity for EGFR, EGFR-HER2, or HER2-HER4, although the relative degree of dependence on EGFR or HER4 signaling varied between different NRG1 fusion-positive cancers. CONCLUSIONS: Our findings indicate that pan-HER inhibition including HER4 and EGFR blockade is more effective than selectively targeting HER3 or HER2-HER3 in NRG1 fusion-positive cancers.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Udagawa H, Nilsson MB, Robichaux JP, et al. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. J Thorac Oncol. 2023. PMID: 37678511. doi:10.1016/j.jtho.2023.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。